Roche and reMYND enter into a strategic alliance to develop treatments for Parkinson’s and Alzheimer’s disease
Roche and reMYND announced that they have entered into an agreement to develop novel therapeutics that could slow down neurodegeneration in Parkinson’s and Alzheimer’s patients by inhibiting alpha-synuclein and tau toxicity.
The collaboration will focus on two of reMYND’s pre-clinical small molecule programmes targeting alpha-synuclein and tau related pathologies in appropriate model systems as well as potential back-up classes. Roche and reMYND will form joint teams to progress the programmes towards clinical studies. Roche will provide input into chemistry, lead-optimisation and pre-clinical development, while reMYND will continue to conduct non-clinical pharmacology studies and further elucidate the underlying molecular mechanisms. Roche will be responsible for all clinical development and worldwide commercialisation.
Under the agreement, reMYND could receive over half a billion Euros in milestone payments, additional FTE payments and royalties on resulting net sales, potentially reaching a double-digit level.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
